Is There a Rationale for High-Dose Chemotherapy as First Line Treatment of Advanced Hodgkin's Disease?
- 1 January 1995
- journal article
- review article
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 15 (sup1) , 47-49
- https://doi.org/10.3109/10428199509052706
Abstract
(1995). Is There a Rationale for High-Dose Chemotherapy as First Line Treatment of Advanced Hodgkin's Disease? Leukemia & Lymphoma: Vol. 15, No. sup1, pp. 47-49.Keywords
This publication has 4 references indexed in Scilit:
- Intensive therapy with cyclophosphamide, carmustine, etoposide +/- cisplatin, and autologous bone marrow transplantation for Hodgkin's disease in first relapse after combination chemotherapy [see comments]Blood, 1994
- A numerical prognostic index for clinical use in identification of poor-risk patients with Hodgkin's disease at diagnosisEuropean Journal of Cancer and Clinical Oncology, 1991
- Prognostic factors among 185 adults with newly diagnosed advanced Hodgkin's disease treated with alternating potentially noncross-resistant chemotherapy and intermediate-dose radiation therapy.Journal of Clinical Oncology, 1990
- The presentation haemoglobin level in 1103 patients with Hodgkin's disease (BNLI report no. 21)Clinical Radiology, 1983